Neuroscience Milestone: This Company Presents Major Alzheimer's Treatment

BioXcel Therapeutics' TRANQUILITY II Phase 3 Trial: A Beacon of Hope for Alzheimer's Patients.

BioXcel Therapeutics, a trailblazer in the field of neuroscience, has recently released promising results from its TRANQUILITY II Phase 3 Trial. The study investigated the efficacy of BXCL501, an innovative treatment for acute agitation in patients with Alzheimer's disease. These positive findings have sparked new hope in the fight against this devastat…